Recent Updates
Recently added Catalysts
BAX Positive Sentiment

Baxter's Room Temperature HEMOPATCH Sealing Hemostat Gains Momentum in Australia and New Zealand Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration of Hemopatch Sealing Hemostat, launched...

Tuesday, January 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Baxter Healthcare has reported positive reception for its room temperature Hemopatch Sealing Hemostat in Australia and New Zealand. Launched earlier this summer, the product has been embraced by surgical teams for its convenience, versatility, and effective clinical performance. This growing success highlights the product's potential impact in surgical settings.
Price reaction · baseline $20.11 (2026-01-16 close) · hit after-hours · 1 other BAX headline(s) in the window, move may be shared
day 0 close · peak
-3.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enthusiastic adoption by surgical teams.
  • Product offers convenience and versatility.
  • Strong clinical performance reported.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+18%
120-day peak, hindsight
Typical move
1.9%
average across 12 past catalysts
Lead asset
Dianeal
Phase 3 · End Stage Renal Disease (ESRD)

Full Press Release Details

DEERFIELD, Ill.,Jan. 21, 2026/PRNewswire/ -- Baxter Healthcare is pleased to share the growing success of the room temperature storage configuration ofHemopatchSealing Hemostat, launched earlier, this Summer, across Australia and New Zealand. Since its introduction, the product has been met with enthusiastic adoption by surgical teams who value convenience, versatility, and clinical performance.

Frequently Asked Questions

What is the Hemopatch Sealing Hemostat?

The Hemopatch Sealing Hemostat is a surgical product designed for hemostasis.

Where has the Hemopatch been launched?

It has been launched in Australia and New Zealand.

What are the benefits of the Hemopatch?

It offers convenience, versatility, and strong clinical performance.

How has the product been received by surgical teams?

Surgical teams have shown enthusiastic adoption of the product.

ShareAdd on Google
Tags: BAX Viatris Investor Conferences Healthcare Baxter Hemopatch Sealing Hemostat Australia New Zealand
Last updated: Jan 20, 2026

Biotech snapshot

Cash runway
$2151M liquidity · $0M/mo burn
Low dilution risk
Lead asset
DianealPhase 3
End Stage Renal Disease (ESRD) →

Catalyst track record

+18%
best trade around BAX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for BAX.

See every catalyst's timing & PoA →